pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PATH · news · pharmadog
← back to PATH
News mentioning PATH
183
stories
15h
Ultragenyx, after setbacks, nabs first gene therapy approval
biopharma dive
18h
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
18h
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
biospace
18h
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
20h
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Trump picks White House aide Heidi Overton as FDA chief: Reports
biospace
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
1d
Opinion: AI has created a shadow medical system
stat
2d
With China rising, Hong Kong builds bridge to biotech innovation
biospace
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
2d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
2d
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
biospace
3d
Assessing shared failures with AI is key to cell and gene therapy’s evolution
biospace
3d
EyePoint plummets on pivotal data for main drug
biopharma dive
3d
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
biospace
6d
Capricor soars on potential FDA review extension, filing amendments
biospace
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
7d
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
biospace
7d
Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo
endpoints
7d
Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100M
biospace
7d
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
8d
Psychedelics developer Definium scores more positive data for LSD pill
biopharma dive
8d
After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
fiercebiotech
8d
Why a missed promotion isn't always about you
biospace
9d
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
9d
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
stat
← prev
page 1 of 7
next →
